New Delhi Defense Ministry on Tuesday announced that Prussian blue insoluble formulation, a vital drug developed under the Technology Development Fund for Radiological and Nuclear Emergencies, has been approved by the Drugs Controller General of India (DCGI).
“Manufacturing and marketing license for commercial use of Prussian blue insoluble formulations developed under the Technology Development Fund (TDF) scheme has been granted by Drugs to Scott-Edil Pharmacia Ltd., Baddi, Himachal Pradesh and Scentr Lifescience LLP, Ahmedabad, Gujarat . Controller General of India (DCGI),” the ministry said.
The drug – the ‘Prussian Blue’ insoluble formulation – was developed by industry based on technology from the Institute of Nuclear Medicine and Allied Sciences (INMAS), Delhi, a laboratory of the Defense Research and Development Organization (DRDO).
It said the drug will be available under the trade names of Pru-DecorpTM and Prudecorp-MG.
“The sources are used for decontamination of Cesium and Thallium and its Active Pharmaceutical Ingredient (API). It is one of the critical drugs listed by the World Health Organization (WHO) for radiological and nuclear emergencies,” the ministry said .
Sameer V Kamat, Secretary, Department of Defense Research and Development and Chairman, DRDO has congratulated the organization as well as the industry on this achievement.
He said that the development of these drugs under TDF project and approval from DCGI is a successful effort of DRDO to promote the industry to achieve Prime Minister Narendra Modi’s vision of ‘Atmanirbhar Bharat’.
catch all business News, market news, today’s fresh news events and Breaking News Update on Live Mint. download mint news app To get daily market updates.